Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The FDA has approved medications like Zepbound and Wegovy for weight loss, which use the same active ingredient as the ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

While research suggests having a higher weight may increase your risk for certain conditions, people can be healthy at every ...